Jaguar Animal Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Animal Health, Inc. on June 9, 2016, reporting events occurring on June 8, 2016. The filing details the entry into a material definitive agreement to raise capital through a common stock purchase agreement.
Key Financial Metrics and Transaction Details
The filing does not provide standard financial metrics such as revenue, profit, cash flow, or debt levels. The primary financial data relates to the new financing arrangement:
- Total Commitment: Aspire Capital Fund, LLC is committed to purchase up to $15.0 million of the Company's common stock over a 30-month term.
- Initial Sale: Upon execution, the Company sold 222,222 shares at $2.25 per share, generating $500,000 in proceeds.
- Commitment Shares: The Company issued 456,667 shares of common stock to Aspire Capital as consideration for entering the agreement.
- Use of Proceeds: Expected to be used for working capital, general corporate purposes, and business development.
Material Changes and Agreement Terms
The Company entered into a Common Stock Purchase Agreement and a Registration Rights Agreement with Aspire Capital. Key terms include:
- Pricing Mechanism: The purchase price is the lesser of the lowest sale price on the purchase date or the average of the three lowest closing prices over the preceding ten trading days. A Volume-Weighted Average Price (VWAP) option allows purchases at 97% of the VWAP.
- Volume Limits: The Company may direct purchases of up to 100,000 shares per business day. VWAP notices are limited to 30% of the aggregate shares traded on the principal market on the purchase date.
- Price Floor: No sales may occur if the closing sale price is less than $0.50.
- Control: The Company controls the timing and amount of sales; Aspire Capital has no right to require sales but is obligated to purchase as directed.
- Covenants: There are no financial or business covenants, restrictions on future funding, or penalties for termination by the Company.
Outlook, Risks, and Contingencies
The filing contains forward-looking statements regarding potential future sales and pricing. The Company notes that actual results may differ materially from expectations. Risks associated with the agreement include market volatility affecting the purchase price and the dilution of existing shareholders due to the issuance of up to $15.0 million in stock. The agreement may be terminated by the Company at any time without cost.
Key Facts for Investor Verification
- Verify the total number of shares outstanding post-transaction to assess dilution impact.
- Confirm the status of the registration statement required to register the shares sold to Aspire Capital.
- Monitor the Company's utilization of the $15.0 million credit facility and the frequency of purchase notices.
- Review the Company's cash position to determine the immediate necessity of drawing down the facility.
- Check for any subsequent filings regarding the actual execution of VWAP or standard purchase notices.